At presentation
| | | |
Creatinine (μmol/l)
|
140 ± 90
|
370 ± 259
|
0.000
|
eGFR (ml/min/1.73 m2)
|
56 ± 31
|
22 ± 22
|
0.000
|
CRP (mg/l)
|
48 ± 61
|
105 ± 82
|
0.001
|
Haemoglobin (g/l)
|
116 ± 21
|
94 ± 18
|
0.000
|
Albumin (g/l)
|
34 ± 6
|
29 ± 6
|
0.000
|
Dialysis-requiring
|
1a
|
20
|
0.000
|
VDI
|
0
|
0
|
1
|
Induction period (~3 months)
|
Number (%) of patients receiving
|
Glucocorticoids
|
46 (100)
|
58 (100)
|
1
|
CYC
|
23 (50)
|
45 (78)
|
0.004
|
Rituximab
|
15 (33)
|
7 (12)
|
0.03
|
CYC and/or rituximab
|
38 (83)
|
52 (90)
|
0.39
|
MMF
|
8 (17)
|
16 (28)
|
0.24
|
Methotrexate
|
8
|
0
|
0.001
|
Azathioprine
|
6
|
1
|
0.02
|
Infliximab
|
1
|
0
|
0.25
|
Cumulative glucocorticoid dose (g)
|
2.5 ± 0.4
|
2.3 ± 0.2
|
0.000
|
Cumulative CYC dose (g)
|
8.0 ± 3.6
|
5.4 ± 3.0
|
0.002
|
Disease remission
| | | |
Number (%) entering remission
|
44 (96)
|
57 (98)
|
0.98
|
Time to remission (days)
|
118 ± 124
|
83 ± 39
|
0.046
|
At 12 months
| | | |
Creatinine (μmol/l)
|
120 ± 46
|
191 ± 172
|
0.02
|
eGFR (ml/min/1.73 m2)
|
56 ± 24
|
43 ± 24
|
0.02
|
CRP (mg/l)
|
22 ± 71
|
8 ± 14
|
0.33
|
Haemoglobin (g/l)
|
126 ± 14
|
121 ± 15
|
0.15
|
Albumin (g/l)
|
41 ± 6
|
40 ± 5
|
0.31
|
Dialysis-requiring
|
0
|
5
|
0.04
|
VDI
|
1.2 ± 0.2
|
1.3 ± 0.1
|
0.79
|
Disease relapse
| | | |
Number (%) of patients with relapses
|
12 (26)
|
8 (14)
|
0.09
|
Mean time to first relapse (days)
|
714 ± 699
|
564 ± 318
|
0.38
|
Median time to first relapse
|
800 (1124)
|
773 (1164)
|
0.57
|
(days & IQR)
| | | |